Robotic Assisted Transanal Total Mesorectal Excision Surgery for Rectal Cancer in Low Site

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University50 enrolled

Overview

To investigates the feasibility, practicability, safety and subjective as well as functional outcome of Robotic transanal total mesentery excision for rectal cancer in low site.

Transanal total mesorectal excision (TaTME) may offer a better way to achieve radical resection and functional protection for lower rectal cancer, which have been regarded as challenging situations in rectal cancer surgery. However, the narrow angle and limited space of the operation restrict the wide spread of this technique. Da Vinci robotic system has achieved good results in rectal cancer surgery. Robotics may help to overcome technical difficulties in TaTME. The purpose of this study was to explore the availability of Da Vinci robotic-assisted transanal total mesorectal excision(R-TaTME) This study investigates the feasibility, practicability, safety and subjective as well as functional outcome of Robotic transanal total mesentery excision for rectal cancer in low site.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Rectal Neoplasms

Interventions

R-TMEPROCEDURE

Conventional Robotic Total Mesentery Excision

R-TaTMEPROCEDURE

Robotic Transanal Total Mesentery Excision

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adenocarcinoma of the rectum by biopsy * the lower edge of the tumor from the anal margin less than 8cm according to MRI or rigid endoscopy * tumor diameter less than 4cm * baseline clinical stage I-III: cT1-3 N0-2 M0 (AJCC v7) * tolerable to surgery * be able to understand and willing to participate in this trial with signature Exclusion Criteria: * history of malignant colorectal neoplasia * recent diagnosis with other malignancies * patients requiring emergency surgery such as obstruction，perforation and bleeding * tumor involving adjacent organs, anal sphincter, or levator ani muscle muti-focal colorectal cancer * preoperative poor anal function, anal stenosis, anal injury, or fecal incontinence history of inflammatory bowel disease or familial adenomatous polyposis * participating in other clinical trails * History of pelvic radiation * BMI \> 40 * Large uterine fibroids * can not tolerate the surgery * history of serious mental illness * pregnancy or lactating women * preoperative uncontrolled infection * the researchers believe the patients should not enrolled in

Outcomes

Primary Outcomes

Positive rate of circumferential resection margin (CRM) of the specimens

Circumferential resection margin (CRM) is the distance between the deepest point of tumor in the primary cancer and the margin of resection in the retroperitoneum or mesentery by pathological examination. CRM 0-1mm is defined as positive, while \>1mm is negative.

Time frame: 10 days after surgery

Secondary Outcomes

The grade score of the specimens integrity

the quality of the specimens: grade 1 is bad gross specimen which means incomplete mesorectum and pelvic fascia, and muscle layer can be see \>5mm; grade 3 is high quality gross specimen, which means the specimen is cylindrical, mesorectum and pelvic fascia are complete; grade 2 is between 1and 3.

Time frame: 10 days after surgery

The distance between lower tumor margin and the lower reaction margin

the oncological safety of the surgery by pathological examination. Reports should contain the distance between lower tumor margin and the lower reaction margin.

Time frame: 10 days after surgery

postoperative hospital stay

recovery information.

Time frame: 3 years after surgery

disease free survival rate

the oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.

Time frame: 3 years after surgery

overall survival rate

the oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.

Central Contacts

fan li, MD.

CONTACT

+86 023 68757958 levinecq@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.